Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Conditions: Relapsed AML; T(8;21); C-KIT Mutation Intervention: Drug: Dasatinib Sponsor: Institute of Hematology & Blood Diseases Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Hospitals | Leukemia | Research